Pugsley T A, Merker J, Lippman W
Can J Physiol Pharmacol. 1976 Aug;54(4):510-5. doi: 10.1139/y76-070.
The 3-isopropyl (I), 3-cyclohexyl (II) and 3-phenyl (III) analogs of the new antipsychotic drug butaclamol, which contains a 3-tertiary butyl group, and their respective (+)-enantiomers, but not (-)-enantiomers, caused a dose related elevation of rat striatal homovanillic acid concentration, indicative of an increased dopamine (DA) turnover; droperidol also exhibited this activity. The order of activity of the (+)-enantiomers was (butaclamol) approximately II greater than I greater than III. A decrease in striatal DA was observed with (+)-I and (+)-III at the highest dose used, but not at one-half the dose. Each analog antagonized the DA-induced increase in adenyl cyclase (EC 4.6.1.1) activity of olfactory tubercle homogenates, the order of activity of the racemates (except for II) AND (+)-ENANTIOMERS BEING (BUTACLAMOL) APPROXIMATELY I greater than III greater than II. The (+)-enantiomers of butaclamol and analogs were two to four times more potent than their respective racemates, with (+)-butaclamol and (+)-I displaying activity generally equivalent to fluphenazine. The respective (-)-enantiomers were ineffective indicating a stereochemical specificity for DA-receptor blockade. Such analogs presented should be of value in elucidating dopaminergic mechansims.
新型抗精神病药物丁酰苯,其含有一个叔丁基,它的3-异丙基(I)、3-环己基(II)和3-苯基(III)类似物及其各自的(+)-对映体,而非(-)-对映体,会导致大鼠纹状体高香草酸浓度呈剂量相关升高,这表明多巴胺(DA)周转率增加;氟哌利多也表现出这种活性。(+)-对映体的活性顺序为(丁酰苯)约II大于I大于III。在使用的最高剂量下,观察到(+)-I和(+)-III会使纹状体DA减少,但在剂量减半时未观察到这种情况。每种类似物都拮抗DA诱导的嗅结节匀浆腺苷酸环化酶(EC 4.6.1.1)活性增加,外消旋体(除II外)和(+)-对映体的活性顺序为(丁酰苯)约I大于III大于II。丁酰苯及其类似物的(+)-对映体的效力是其各自外消旋体的两到四倍,(+)-丁酰苯和(+)-I的活性通常与氟奋乃静相当。各自的(-)-对映体无效,表明对DA受体阻断具有立体化学特异性。所呈现的此类类似物在阐明多巴胺能机制方面应具有价值。